Several ARSs inhibitors have been applied in the clinical practice including the IRS inhibitor anti-bacterial mupirocin, for the treatment of topical infections caused by G-positive bacteria (Pappa, 1990; Nakama et al., 2001), the LRS inhibitor anti-fungal AN2690, for the treatment of onychomycosis which is caused by dermatophytes (Rock et al., 2007), and the PRS inhibitor anti-protozoal halofuginone, for the treatment of malaria (Samant and Sukhthankar, 2009). The gene discussed is LARS1; the disease is infection.